The 7th Annual PREDiCT: Tumor Models Boston summit will explore robust preclinical strategies utilizing current and emerging model systems to overcome core challenges across the early stages of cancer drug development. Presentations will span preclinical strategies validating new anticancer drugs, assessing therapeutic index and identifying surrogate markers of tumor progression.

Plug into a network of preclinical and translational scientists seeking to share methods for the rational design of combinations, patient stratification and identify new strategies to model metastasis, resistance and sensitivity.

Why attend PREDiCT : Tumor Models Boston ?

• 35+ Preclinical & Translational Oncology Heads, each pioneering the further development and application of experimental models, will be sharing the latest insights on the impact of their work.
• 100+ senior level scientists from Sanofi, Kleo Pharmaceuticals, NIH, Dicerna, Pfizer, Crown Bioscience, The Jackson Laboratory, Eisai and many more are set to review the comparative cost-per-data point of next generation models alongside classical model-systems.
• We’ll explore how classical and emerging models are evolving efficacy determination, biomarker discovery and combination therapies, allowing you to further develop your research and gain the best insight of the industry.

Download the full event guide to find out more!

To learn more about this event, and to register online, visit https://tumor-models.com/